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CancerIn high-risk remission B-precursor acute lymphoblastic leukemia (BPL) patients, relapse rates have remained
high post-hematopoietic stem cell transplantation (HSCT) even after the use of very intensive total body
irradiation (TBI)-based conditioning regimens, especially in patients with a high “minimal residual disease”
(MRD) burden. New agents capable of killing radiation-resistant BPL cells and selectively augmenting their
radiation sensitivity are therefore urgently needed. We report preclinical proof-of-principle that the potency of
radiation therapy against BPL can be augmented by combining radiation with recombinant human CD19-
Ligand × soluble TRAIL (“CD19L–sTRAIL”) fusion protein. CD19L–sTRAIL consistently killed radiation-resistant
primary leukemia cells from BPL patients as well as BPL xenograft cells and their leukemia-initiating
in vivo clonogenic fraction. Low dose total body irradiation (TBI) combined with CD19L–sTRAIL was highly
effective against (1) xenografted CD19+ radiochemotherapy-resistant human BPL in NOD/SCID (NS) mice
challenged with an otherwise invariably fatal dose of xenograft cells derived from relapsed BPL patients
as well as (2) radiation-resistant advanced stage CD19+ murine BPL with lymphomatous features in
CD22ΔE12xBCR-ABL double transgenic mice. We hypothesize that the incorporation of CD19L–sTRAIL
into the pre-transplant TBI regimens of patients with very high-risk BPL will improve their survival outcome
after HSCT.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
B-precursor acute lymphoblastic leukemia (BPL) is the most
common childhood cancer and a major cause of cancer-related mortal-
ity in children and adolescents (Asselin et al., 2013). Total body irradia-
tion (TBI)-based myeloablative pretransplant conditioning regimens
are frequently used in hematopoietic stem cell transplantation (HSCT)
for high-risk remission BPL (Bar et al., 2014; Bachanova et al., 2012;
Bernard et al., 2014; Kalaycio et al., 2011; Pulsipher et al., 2009;
Balduzzi et al., 2014; Tracey et al., 2013; Locatelli et al., 2012; Mori
et al., 2012; Gaynon et al., 2006; Marks et al., 2006). Although TBI-ared that no conﬂict of interest
geles, MS#160, Los Angeles, CA
du (F.M. Uckun).
. This is an open access article undercontaining contemporary conditioning regimens are more effective
than conditioning regimens without TBI (Kalaycio et al., 2011; Marks
et al., 2006), relapse rates have remained high post-HSCT even after
the use of very intensive TBI-based conditioning regimens, especially
in patients with a high minimal residual disease (MRD) burden
(Uckun et al., 1993a; Pulsipher et al., 2009; Balduzzi et al., 2014; Bar
et al., 2014; Bachanova et al., 2012; Asselin et al., 2013), which is in
agreement with our published data demonstrating that BPL cells are
radiation-resistant (Uckun et al., 1993b, 2010a,b,c, 2013, 2015a,b).
New agents capable of killing radiation-resistant BPL cells and selective-
ly augmenting their radiation sensitivity are therefore urgently needed.
Such new agents could provide the basis for innovative and highly
effective conditioning regimens that employ reduced intensity TBI
with substantially reduced toxicity for organs at risk.
Ionizing radiation has been shown to activate the Tumor Necrosis
Factor-Related Apoptosis-Inducing Ligand (TRAIL) signaling pathway
in BPL cell lines, which has been proposed to cooperate synergistically
with the cytotoxic effect of radiation (Kruyt, 2008, Gong et al., 2000).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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to amplify the potency of ionizing radiation against BPL cell lines
(Wissink et al., 2006). Furthermore, the anti-cancer activity of sTRAIL,
aswell as agonistic anti-TRAIL-R antibodies, is potentiated by irradiation
(Fox et al., 2010; Dimberg et al., 2013; Bremer, 2013; Merino et al.,
2007). The anti-cancer activity of recombinant human sTRAIL in preclin-
ical models was more impressive when it was combined with chemo-
therapeutic drugs or radiation (Fox et al., 2010; Dimberg et al., 2013;
Bremer, 2013;Merino et al., 2007).We recently developed the recombi-
nant human CD19L–sTRAIL fusion protein as an apoptosis-inducing
anti-leukemic biotherapeutic agent with favorable safety and pharma-
cokinetic features as well as potent single agent anti-BPL activity
in vivo (Uckun et al., 2015a). The purpose of the present study was to
examine the ability of CD19L–sTRAIL, a potent and selective inducer
of pro-apoptotic TRAIL signaling in CD19-positive BPL cells, to aug-
ment the anti-leukemic potency of low dose TBI in NS mouse xeno-
graft models and CD22ΔE12xBCR double-transgenic (Tg) mouse
models of radiation-resistant BPL. Our study provides preclinical
proof of principle that the anti-leukemic potency of TBI regimens
can be signiﬁcantly augmented by CD19L–sTRAIL at non-toxic dose
levels. Further development of CD19L–sTRAIL plus reduced intensity
TBI as a new conditioning regimen has the potential to signiﬁcantly
improve the event-free survival (EFS) outcome and long-term health
status of high-risk remission BPL patients undergoing HSCT.2. Materials and Methods
2.1. Recombinant Human CD19L–sTRAIL Fusion Protein
A stepwise molecular cloning strategy was employed using the
commercially available pFUSE-hIgG1-Fc2 plasmid (Invivogen, CA) as
the backbone vector to construct an expression cassette for CD19L–
sTRAIL (Uckun et al., 2015a). CD19L–sTRAIL is a fusion protein of sTRAIL
connected to the C-terminus of the CD19L protein through a ﬂexible
linker (Fig. S1A). It was produced in a mammalian expression system,
as recently described in detail (Uckun et al., 2015a). CD19L–sTRAIL
was puriﬁed using anion exchange (AIE) chromatography and size ex-
clusion (SE) chromatography (Fig. S1B1). The presence of the CD19L
and sTRAIL domains was documented by Western blot analysis (Fig.
S1B2 & B3). The CD19-speciﬁc immunoreactivity of CD19L–sTRAIL
was conﬁrmed by demonstrating that ﬂuorescent-labeled CD19L–
sTRAIL binds to the surface membrane of CD19+ human leukemia
cells, but not to CD19 receptor-negative human 293T cells (Uckun
et al., 2015a). The binding of CD19L–sTRAIL to CD19+ human leukemia
cells was mediated via its CD19L domain which was directed to the
CD19 extracellular domain, because it could be blocked by an IgG1-Fc
fusion protein of recombinant human CD19L used as a CD19 receptor-
speciﬁc competitor as well as by a recombinant CD19 extracellular
domain protein (but not by a recombinant CD19 intracellular domain
protein) (Uckun et al., 2015a). CD19L–sTRAIL caused apoptosis in the
CD19 receptor positive ALL-1 cell line in a concentration-dependent
fashion with ~90% apoptosis at 210 fM and N99% apoptosis at 2.1 pM
(Uckun et al., 2015a). CD19L–sTRAIL induced apoptosis of BPL cells
was mediated by the CD19-speciﬁc binding of its CD19L-domain to
BPL cells because (i) the presence of a 20-fold molar excess of soluble
CD19ECD protein that speciﬁcally binds the CD19L domain could sig-
niﬁcantly block the anti-leukemic action of CD19L–sTRAIL, whereas a
20-fold molar excess of soluble CD19ICD protein that was included as
a control protein did not affect its action and (ii) sTRAIL alone did not
cause apoptosis in ALL-1 cells even at a 100 nM concentration
(Uckun et al., 2015a). NHS-Fluorescein (NHSF) (5/6-carboxyﬂuores-
cein succinimidyl ester; excitation wavelength: 494 nm, emission
wavelength: 518 nm — both identical to the same parameters for
FITC; Thermo Scientiﬁc, Waltham, MA) was used for ﬂuorescent
labeling of CD19L–sTRAIL via its primary amines according to themanufacturer's recommendations, as previously described (Uckun
et al., 2015a).
2.2. Leukemia Cells
Primary leukemia cells from 17 BPL patients and 10 BPL xenograft
clones derived from spleen specimens of xenografted NSmice inoculat-
ed with primary leukemia cells from 5 pediatric BPL patients (4 in re-
lapse, 1 newly diagnosed) were used in the described experiments.
The secondary use of leukemic cells for subsequent molecular studies
did not meet the deﬁnition of human subject research per 45 CFR
46.102 (d and f) since it did not include identiﬁable private information,
and it was approved by the IRB (CCI) at the Children's Hospital Los
Angeles (CHLA). We also used CD19+ primary mouse BPL cells from
CD22ΔE12-transgenic (Tg) and CD22ΔE12xBCR-ABL double-Tg mice.
2.3. Flow Cytometry, Immunoﬂuorescent Staining, Western Blot Analyses,
and Apoptosis Assays
Immunoﬂuorescent staining of cells, ﬂow cytometry, immunoblot-
ting using the ECL detection system (Amersham Pharmacia Biotech),
and apoptosis assays were performed, as described in detail in previous
publications (Uckun et al., 2010a,b, 2011a,b, 2012, 2013, 2015a,b).
2.4. Evaluation of the In Vitro Anti-leukemic Potency of CD19L–sTRAIL Plus
Radiation Using Apoptosis Assays
We used primary leukemia cells from 17 patients with BPL as well
as 10 ALL xenograft clones derived from 5 BPL patients to examine
the in vitro anti-leukemic potency of CD19L–sTRAIL + radiation.
Cellswere analyzed for apoptosis at 48 h after the initiation of treatment
using the standard quantitative ﬂow cytometric apoptosis assay with
the Annexin V-FITC Apoptosis Detection Kit from Sigma (St. Louis,
MO), as previously reported (Uckun et al., 2015a; Uckun et al., 2011b,
2013). The labeled cells were analyzed on a LSR II ﬂow cytometer
(Becton Dickinson, Lakes, NJ). The in vitro anti-leukemic potency of
CD19L–sTRAIL plus radiation was documented by comparing the num-
bers of residual viable lymphoid cells in the 48 h cultures of untreated
control cells vs. cells exposed to the test treatments. Speciﬁcally, the
number of viable cells was determined by ﬁrst determining in each
sample the number of lymphoid cells remaining in the P1 lymphoid
window of the FSC vs. SSC light scatter plots using the formula:
N(P1) = 10,000 (i.e. total number of cells analyzed) × % of cells in P1.
Then, we determined the % of viable cells in the P1-window as
the % of Annexin V-FITC− PI− cells in the left lower quadrant of the
Annexin V-FITC vs. PI ﬂuorescence intensity dot plots. The number
of viable lymphoid cells (N[viable]) was then determined using the
formula: N(P1) × % Viable Cells in P1/100. The percent apoptosis
(%A) was calculated using the formula: 100 − N[viable for Test
sample] / N[viable for Control sample] × 100. We constructed a
Mixed Model ANOVA with one factor that identiﬁed the treatment
effect for either primary leukemia cells from BPL patients or BPL xe-
nograft cells for the analysis of the apoptosis data. The statistical
model included a ﬁxed effect (“treatment”) and a random effect
(“case”) that controlled for multiple measurements taken from a
BPL xenograft sample or primary BPL cells. The least squares method
was used to ﬁt the parameters for the general linear model and these
parameters were utilized to generate prediction equations and best-
ﬁt lines were visualized by plotting leverage graphs using standard
coding procedures. We examined the distribution of the residuals
of the model for equal dispersion around the line of best ﬁt to assess
the effect of the boundary values of 0 and 100 on the model. Effect
sizes from differences between treatment least square mean esti-
mates were used in the design of planned linear contrasts to deter-
mine signiﬁcant effects (two-tailed P b 0.05 deemed signiﬁcant
calculated in JMP software [SAS, Cary, NC]). The standard error
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ing differences between group means was obtained from the resid-
uals of the linear ﬁt for all the data and this minimized the effect of
skewed standard deviation estimates from measurements close to
the boundary values. To compare group means between 2 treat-
ments within a single level of a factor, the linear contrast utilized
the standard error derived from the model and the comparison
group means were coded with linear parameter values of 1 and−1
to calculate effect size between the 2 treatments. Linear contrasts
compared treatment of: CD19L–sTRAIL alone with each combination
of CD19L–sTRAIL plus 50, 100 or 200 cGy dose of radiation; radiation
alone (50, 100 or 200 cGy) with each combination of CD19L–sTRAIL
plus 50, 100 or 200 cGy dose of radiation; and, 50 cGy with
200 cGy dose of radiation.
2.5. Evaluation of the Effects of In Vitro CD19L–sTRAIL + Radiation
Treatments on Leukemia-initiating Cells (LICs) in BPL Xenograft Samples
In experiments aimed at evaluating the effects of CD19L–
sTRAIL + radiation (RAD) on the LICs (i.e. putative leukemic stem cell
fractions capable of engrafting and causing overt leukemia in NS mice)
in the BPL xenograft samples, leukemia cells (cell density: 2 × 106
cells per mL) isolated from the spleens of xenografted mice challenged
with primary leukemic cells from a pediatric BPL patient were
(i) irradiated with 2 Gy γ-rays (N = 11), (ii) treated for 24 h at 37 °C
with CD19L–sTRAIL at a concentration of 2.1 pM (N= 14), (iii) treated
with 2 Gy γ-rays + 2.1 pM CD19L–sTRAIL (24 h incubation at 37 °C)
(N = 4), or (iv) left untreated for 24 h at 37 °C and then reinjected
(N = 12). We compared the effects of CD19L–sTRAIL plus radiation vs.
other treatments on the ability of the LICs in BPL xenograft specimens
to engraft and cause fatal leukemia in NS mice, as previously described
(Uckun et al., 2013, 2015a). For the analysis of the in vitro potency of
various treatments against the LICs in xenograft specimens, we com-
pared the mean spleen size, spleen cellularity as well as absolute lym-
phocyte counts (ALCs) of mice inoculated with xenograft cells that
were subjected to these treatments prior to injection (radiation: 24 h
culture at 37 °C followed by 2 Gy γ-ray exposure immediately prior to
injection; CD19L–sTRAIL: 24 h incubation at 37 °C prior to injection;
radiation+ CD19L–sTRAIL: 24 h incubationwith CD19L–sTRAIL follow-
ed by 2Gyγ-ray exposure immediately prior to injection). For statistical
analysis of the data, we employed both Independent T-tests with
correction for unequal variance (Microsoft Excel) where appropriate
and Linear Contrasts that were constructed from Mixed Model ANOVA
for spleen size and nucleated spleen cell counts (Log10 transformed).
P-values less than 0.05 were deemed signiﬁcant if the False Discovery
Rate was less than 10%.
2.6. Transgenic (Tg) Mice
The CD22ΔE12-transgenic (Tg) mouse model of BPL was recently
described (Uckun et al., 2015b). CD22ΔE12xBCR-ABL double-Tg mice
were established by breeding commercially obtained male BCR-ABL
(p190) Tg founder mice (B6.Cg-Tg (BCR-ABL) 623Hkp/J, Jackson Labs)
with female CD22ΔE12-Tg mice. Pups were screened for the presence
of the BCR-ABL and CD22ΔE12 transgenes by PCR analysis of tail DNA:
the CD22ΔE12-Tg amplicon of 391 bp was detected as previously
described (Uckun et al., 2014, 2015b). DNA was also ampliﬁed with a
BCR-ABL Tg forward primer agagatcaaacaccctaacct and a BCR-ABL Tg
reverse primer ccaaagccatactccaaatgc for an expected amplicon of
417 bp. Double-Tg mice were identiﬁed by PCR detection of both
transgenes in their genomic DNA samples (Fig. S2).
2.7. Standard Chemotherapy Drugs
We used the standard chemotherapy drugs commonly used in B-
precursor ALL therapy, including Vincristine (Lot #: X067139A;Manufacturer: Hospira Inc., Lake Forest, IL), PEG-Asparaginase
(Oncospar; Lot #: 0009A; Manufacturer: Enzon Pharmaceuticals Inc.,
Bridgewater, NJ); as well as Dexamethasone (Cat. #: D9184-100MG;
Sigma, Saint Louis, MO) as controls. Imatinib was obtained from the LC
Labs (Cat# BCK-104; Woburn, MA). The chemotherapy drugs were ob-
tained from the Pharmacy of the Children's Hospital Los Angeles.
2.8. Irradiation of Cells and Mice
NS mice and Tg mice with advanced leukemia were placed in
autoclaved 2 L Pyrex Grifﬁn glass beakers (VWR, Radnor, PA) and irradi-
atedwith single dose TBI (2Gy for NSmice/4 Gy for transgenic leukemic
C57BL/6 mice) delivered at 106 cGy per min using a self-shielded Cs-
137 irradiator (Mark I Irradiator-68A, JL Sheperd & Associates, San
Fernando, CA), as previously reported (Uckun et al., 2010c). Cells were
irradiated with 50–200 cGy γ-rays in a single exposure using the Mark
I Cs-137 irradiator (Uckun et al., 2010c, 2013).
2.9. Evaluation of the Safety and Efﬁcacy of Systemic CD19L–sTRAIL + Low
Dose TBI Regimen in a NS Mouse Model of Relapsed BPL
The anti-leukemic activity and toxicity of CD19L–sTRAIL + TBI com-
bination therapy were studied in a NS mouse model of human BPL
(Uckun et al., 2013, 2015a). NS mice (NOD.CB17-Prkdcscid J; 4–6 weeks
of age at the time of purchase, female) were obtained from the Jackson
Laboratory (Sacramento, CA). The research was conducted according to
Institutional Animal Care and Use Committee (IACUC) Protocol # 280-
12 that was approved on 7-10-2012. All animal care procedures
conformed to the Guide for the Care and Use of Laboratory Animals
(National Research Council, National Academy Press, Washington DC
1996, USA). The speciﬁc pathogen-free (SPF) environment for immuno-
deﬁcient NSmicewas ensured by the use ofMicro-Isolator cages, which
were autoclaved, completewith rodent chow and hardwood Sani-Chips
for bedding.Water was provided ad libidum andwas also autoclaved as
well as supplemented with Bactrim or Septra (0.89 mg per mL sulfa-
methoxazole, 0.18 mg per mL trimethoprime) by adding 22.75 mL of
Bactrim or Septra to each liter of water once per week as prophylaxis.
A light and dark cycle of 12 h each was strictly adhered to, as was a
room temperature of 70–75 °F. Animals remained within the conﬁnes
of the Micro-Isolators except for scheduled cage changes and treat-
ments, which were performed in a laminar ﬂow hood. Ibuprofen was
used as a pain reliever to reduce the discomfort associated with treat-
ment or inoculation of leukemia cells. The ﬁrst 2 independent experi-
ments (20 mice per experiment) were aimed at evaluating the safety
of the CD19L–sTRAIL + TBI combined immunoradiotherapy regimen
and its ability to prevent leukemia initiating cell (LICs) fractions of the
i.v. inoculated xenograft clones from causing fatal leukemia in NS
mice. These xenograft clones were derived from primary leukemia
cells of two pediatric BPL patients in relapse. NSmice (6–8week old, fe-
male, same age in all cohorts in each independent experiment)were in-
oculated intravenously (iv) with ALL xenograft cells (2 × 106 leukemia
cells in 0.2 mL PBS) via tail vein injection with a 27-gauge needle. All
NOD/SCID mice were genetically identical, of the same age, and in
each experiment all mice were inoculated with the same number of
BPL cells from the identical BPL xenograft clone. This statistical equiva-
lency of mice allowed the use of a pseudo-randomization convenience
allocation to assignmice to identiﬁed cages. For random treatment allo-
cation, cages were randomly selected to receive one of the speciﬁed
treatments. Mice were treated with 2 Gy TBI alone, CD19L–sTRAIL
alone (17 fmol per kg per day i.v. on days 1 and 2), or with CD19L–
sTRAIL + 2 Gy TBI (CD19L–sTRAIL on days 1 and 2 at 17 fmol per kg
per day i.v. plus 2 Gy TBI on day 2, 1 h after CD19L–sTRAIL injection).
Untreated mice challenged with the same number of leukemia cells
were included as controls (CON). Mice were monitored daily and
electively euthanized by CO2 asphyxia when any mouse developed
morbidity. Blood was collected by cardiac puncture after euthanasia
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CA) blood analyzer and (ii) standard serum chemistry tests using an
Olympus AU5400 (Sacramento, CA) instrument. Bone marrow function
was assessed by complete blood counts (CBCs) as well as microscopic
bone marrow examinations. Liver toxicity was assessed with measure-
ments of serum levels of ALT, alkaline phosphatase (Alk. Ptase.), total
bilirubin, and albumin. Pancreas toxicity was assessed with measure-
ments of serum amylase and lipase levels. Renal toxicity was assessed
with measurements of serum creatinine and BUN levels. Two-sample
Student's T-tests (degrees of freedom adjusted for unequal variances)
were performed to assess the signiﬁcance of the differences in spleen
counts, CBCs or blood chemistry values between treatment groups. P-
values of less than 0.05 were deemed signiﬁcant and not corrected for
multiple comparisons if the false discovery rate was less than 10% for
the number of comparisons that were performed across all the pairwise
treatment groups and CBCs and Blood Chemistry measurements. Pe-
ripheral smears were stained with Wright–Giemsa and examined mi-
croscopically for the presence of circulating leukemia cells. Images
were taken with an EVOS XL Core Light Microscope (AMG Bothel,
WA) using a 40× objective. The spleens of mice were removed and
measured, and cell suspensions were prepared for determination of
mononuclear cell counts. At the time of necropsy, 19 different tissues
(bone, bone marrow, brain, spinal cord, uterus, ovary, heart, thyroid
gland, large intestine, small intestine, kidney, liver, lymph node, lungs,
pancreas, peripheral nerve, skeletal muscle, thymus, urinary bladder)
were collected within 15 min after sacriﬁce. Organs were preserved in
10% neutral phosphate buffered formalin and processed for histologic
sectioning. For histopathologic studies in 20mice (5mice per treatment
group), formalin ﬁxed tissueswere dehydrated and embedded in paraf-
ﬁn by routine methods. Glass slides with afﬁxed 4–5 micron tissue sec-
tions were prepared and stained with Hematoxylin and Eosin (H&E).
The brain, liver, kidney, lymph nodes, and bonemarrowwere examined
for their leukemic involvement. Organswere examined for toxic lesions.
Images were taken with an EVOS XL Core Light Microscope (AMG
Bothel, WA) using 20× and 40× objectives or a Nikon Eclipse Ci camera
(Melville, NY) equipped with a Nikon Digital Sight DS-U3 microscope
camera controller and Nikon's advanced imaging software suite NIS-
Elements. We next examined the effects of the CD19L–sTRAIL + TBI
regimen on the survival outcomeof xenograftedNSmicewith advanced
and symptomatic leukemia. NSmice (6–8week old, female, same age in
all cohorts in each independent experiment) were inoculated intrave-
nously (iv) with ALL xenograft cells derived from a relapsed pediatric
BPL patient (2 × 106 leukemia cells in 0.2 mL PBS) via tail vein injection
with a 27-gauge needle. Treatments were initiated on day 10 after the
inoculation of xenograft cells unless mice became symptomatic from
their leukemia earlier. Our previous studies using our NS mouse
model of aggressive BPL (Uckun et al., 2015a) exhibited a median sur-
vival time of 17 days (standard deviation = 2 days). A prospective
power analysis (2 sample means; JMP, SAS, Cary, NC) testing for a
treatment-induced doubling of the median survival time required a
total sample size of 6 mice (viz.: 3 mice per group comparing 2 groups)
at a 1% signiﬁcance level and 95% power. A two-sample, one-sided pro-
spective power analysis (exact binomial distribution)was performed to
calculate the sample size required per group in a pair-wise comparison
to document a statistically signiﬁcant increase in 60-day survival out-
come from 5% (single modality) to 60% (combination modality). This
analysis showed that 8 mice per group would be required to document
this difference at a 5% signiﬁcance level and 80% power. All NOD/SCID
micewere genetically identical, of the same age, and in each experiment
all mice were inoculated with the same number of BPL cells from the
identical BPL xenograft clone. This statistical equivalency of mice
allowed the use of a pseudo-randomization convenience allocation to
assign mice to identiﬁed cages. For random treatment allocation, cages
were randomly selected to receive one of the speciﬁed treatments
based on the results of the power analyses regarding the required min-
imum sample sizes for each treatment group.We allocated a larger thanminimally required number of mice to the CD19L–sTRAIL and CD19L–
sTRAIL + TBI treatment groups for more accurate determination of
the potential toxicities and tissue collection at the time of death for fu-
ture molecular biomarker discovery research. We applied concealment
of treatment allocation and blind outcome assessment to reduce the risk
of bias in our conclusions. Daily health care assessments were per-
formed by animal care technicians not involved in the treatment assign-
ments or treatments who alsomade the determinations about which of
the mice needed to be electively sacriﬁced to meet the humane end-
points criteria in laboratory animal experimentation. Investigators did
not participate in individual health status or outcome assessments. Alto-
gether, 11 CON mice were left untreated. Twenty-three mice with
symptomatic xenograftedBPLwere treatedwith CD19L–sTRAIL as a sin-
gle agent (24 fmol per kg over 2 days with commencement on day 6
(N = 10) or 51 fmol per kg over 3 days with commencement on day
10 (N = 13)). Eleven mice received 2 Gy TBI either on day 7 (N = 5)
or day 11 (N=6). Sevenmicewere treatedwith chemotherapy admin-
istered as a cocktail on day 10: Vincristine (0.05 mg per
kg) + Dexamethasone (2 mg per kg) + PEG-Asparaginase (850 IU per
kg). Sixteen test mice with symptomatic xenografted leukemia were
treated with CD19L–sTRAIL (24 fmol per kg over 2 days with com-
mencement on day 6 plus 2 Gy TBI on day 7 (N = 5) or 51 fmol per
kg CD19L–sTRAIL over 3 days with commencement on day 10 plus
2 Gy TBI on day 11 (N = 11)). For the analysis of the NS mouse xeno-
graft data on the in vivo potency of CD19L–sTRAIL + low dose TBI vs.
other treatments, event-free survival (EFS) times were measured from
the day of inoculation of xenograft cells to the day of death or killing
of the test mice treated with CD19L–sTRAIL + TBI or other treatments.
The probability of survival was determined and the event-free interval
curves were generated using the Kaplan–Meier product limit method,
as in previous studies (Uckun et al., 2013, 2015a,b). Log-rank tests
were performed to compare differences in median survival estimates
between all groups and pairwise comparison of the individual treat-
ment groups.
2.10. Evaluation of the Efﬁcacy of the Systemic CD19L–sTRAIL + Low Dose
TBI regimen in CD22ΔE12xBCR-ABL Double Transgenic Mice with
Advanced BPL
CD22ΔE12xBCR-ABL double-Tg mice spontaneously develop fatal
BPL with lymphomatous features at a median of 78 days (Fig. S2). For
mice randomly assigned to this project, a prospective power analysis
(One-sample proportions using the exact method based on a binomial
distribution, One-sided test; JMP, SAS, Cary, NC) showed that a sample
size of 6 mice per treatment group would be required to demonstrate
an increase in the proportion of CD22ΔE12xBCR-ABL double-Tg mice
surviving at 4 weeks from the onset of symptomatic leukemia from a
baseline of 0% to 40% with a speciﬁc treatment at a 5% signiﬁcance
level and 95% power. Therefore, it was determined that using a group
size of 6 mice would make a comparative study sufﬁciently powered
to detect treatment-related large effect sizes. We also performed a
two-sample, one-sided prospective power analysis (exact binomial dis-
tribution) to calculate the sample size required for each treatment
group in a pairwise comparison to observe an increase in 4-week sur-
vival outcome from 10% (single modality) to 65% (combination modal-
ity). This analysis showed that a sample size of 9 mice per group (18 in
total)would be required to detect a change in 4-week survival from 10%
to 65% with 5% signiﬁcance at 80% power. We allocated a larger than
minimally required number of mice to the CD19L–sTRAIL and CD19L–
sTRAIL + TBI treatment groups (i.e. 10 mice/group) for more accurate
determination of the potential toxicities of the combined modality and
tissue collection at the time of death for futuremolecular biomarker dis-
covery research. Leukemic double-Tg mice were randomly assigned an
identifying number and a random sequence of mouse numbers was de-
termined by picking out index cards without replacement on days mul-
tiple mice developed leukemia. Each leukemic mouse in sequence was
Fig. 1. In vitro anti-leukemic potency of CD19L–sTRAIL and CD19L–sTRAIL + low dose
radiation against primary BPL cells and ALL xenograft clones. [A & B] The bar charts depict
the mean (±SEM) percentage of apoptosis in human BPL cells treated with ionizing radi-
ation (RAD) (dose levels: 50, 100, or 200 cGy), CD19L–sTRAIL (2.1 pM) or RAD+ CD19L–
sTRAIL. The percentage of apoptosis was determined as described in the Materials and
Methods section. Panel A depicts the results obtained using BPL xenograft clones. Panel
B shows the cumulative data on xenograft clones plus primary leukemia cells from BPL pa-
tients. [C] CD19L–sTRAIL was examined for its ability to abrogate the ability of leukemia-
initiating BPL xenograft cells derived from BPL patients to cause leukemia in NS mice.
ALL xenograft cells (2 × 106 cells/sample) were treated with 2.1 pM CD19L–sTRAIL for
24 h at 37 °C and then irradiated with 2 Gy γ-rays. Controls included untreated cells as
well as cells that were cultured for 24 h at 37 °C without the addition of CD19L–sTRAIL
and then irradiated with 2 Gy γ-rays. Cells were washed in PBS, resuspended in PBS and
inoculated into NSmice intravenously via tail vein injections in a 200 μL total volume.Mice
were monitored for signs of leukemia and all mice in a given experiment were sacriﬁced
when any mouse developed morbidity. The bar graphs show for each treatment group
the average (mean ± SEM) Log10-transformed nucleated spleen cell count. CD19L–sT:
CD19L–sTRAIL.
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cards with replacement designating each of the 4 treatment groups
(Group 1: No treatment; Group 2: TBI alone; Group 3: CD19L–sTRAIL
alone at 17 fmol per kg per day i.v. for 1–3 days; Group 4: CD19L–sTRAIL
at 17 fmol per kg per day i.v. for 1–3 days + 4 Gy TBI at 1 h post the 1st
CD19L–sTRAIL injection) for random assignment of treatment groups.
Treatments were initiated within 2 days after the onset of symptomatic
leukemia or detection of measurable tumor masses. The number of
CD19L–sTRAIL treatments in Groups 3 and 4 depended on the day ther-
apy was initiated as treatments could only be given during weekdays.For example, whereas a Group 4 mouse starting on therapy on Mon-
day–Wednesday received 3 daily treatments of CD19L–sTRAIL, a
Group 4 mouse starting on therapy on Friday could only receive one
dose of CD19L–sTRAIL. Of the 11 mice in Group 4, 5 received a single
dose of CD19L–sTRAIL followed by 4 Gy TBI and 6 received 3 doses of
CD19L–sTRAIL plus 4 Gy TBI administered on day 1 at 1 h post CD19L–
sTRAIL. After the completion of the planned allocations, 6 additional
mice were randomized to receive CD19L–sTRAIL alone or Imatinib
alone by random assignment of these 2 treatment groups using index
cards picked out of a containerwith replacement. The treatment assign-
ments were performed to obtain CD19L–sTRAIL-resistant and Imatinib-
resistant BPL cells for future molecular biomarker discovery research.
No objective responses were observed in either group. The data from
the CD19L–sTRAIL treated mice were combined with the data from
the other CD19L–sTRAIL treated mice in Group 3 to eliminate any bias
in effect size assessment. Overall, 7 mice received 3 doses and 1
mouse received 2 doses of CD19L–sTRAIL as a single agent. We used
this randomization combinedwith concealment of treatment allocation
and blind outcome assessment to reduce the risk of bias in our conclu-
sions. Animal care technicians not involved in the treatment assign-
ments or treatments performed daily health care assessments.
Investigators did not participate in individual health status or outcome
assessments. In addition, any unintended intergroup differences in ini-
tial tumor size were formally excluded by statistical comparisons. The
initial tumor size was comparable among groups, as measured by the
longest diameter: 1.0 ± 0.1 cm for CON (N = 8), 1.0 ± 0.1 cm for TBI
(N = 5), 1.2 ± 0.2 cm for CD19L–sTRAIL (N = 8), and 1.1 ± 0.1 cm
for CD19L–sTRAIL+ TBI (N= 11) (One-way ANOVA, P = 0.5). Statisti-
cal analyses were performed by a bioinformatics expert (S.Q.) who was
not involved in treatment assignments, treatments, or outcome assess-
ments. Themasseswere photographed using an iPhone 4S (Los Angeles,
CA) equipped with an 8-megapixel iSight camera and the dimensions
weremeasured at indicated time points in order to determine the effect
of the treatments on disease progression. The tumor-free survival (TFS)
(duration of tumor-free interval), progression-free survival (PFS) (time
from initiation of therapy to 10% increase in the longest diameter of
tumormass), and overall survival (OS) (time from onset of symptomat-
ic leukemia to the day of death or killing) were determined for each
treatment group. Signiﬁcance of pairwise differences in median values
between treatment groups for TFS and PFS times was assessed using
Non-parametric Wilcoxon Tests (JMP Software v10.02, SAS, Cary, NC).
The probability of OSwas determined and the event-free interval curves
were generated using the Kaplan–Meier product limit method, as in
previous studies (Uckun et al., 2013, 2015a,b). Log-rank tests were per-
formed to compare differences inmedian survival estimates between all
groups and pairwise comparison of the individual treatment groups.
Post-treatment tumor size (longest diameter) was normalized to day
1measurements. Tumor growth proﬁles of control mice andmice treat-
ed with the CD19L–sTRAIL + low dose TBI regimen were compared
using a repeated measures analysis of covariance controlling for
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and mice variance components; JMP Software v10.02, SAS, Cary, NC).
The model was comprised of a ﬁxed factor (“treatment”), time co-
variate (“day”), interaction term (“treatment × day”) and a random fac-
tor (Mouse ID). F-test comparing the least squaremeans for control ver-
sus CD19L–sTRAIL + TBI means calculated in the ﬁxed factor was
utilized to assess the signiﬁcance of overall remission or reduction of
tumor size (P-values b 0.05 deemed signiﬁcant). The probability of sur-
vival (OS)was determined and the event-free interval curveswere gen-
erated using the Kaplan–Meier product limit method, as in previous
studies (Uckun et al., 2013, 2015a,b). Log-rank tests were performed
to compare differences inmedian survival estimates between all groups
and pairwise comparison of the individual treatment groups.
2.11. Statistics
Standard methods were used for statistical analysis of data (Uckun
et al., 2013, 2015a,b). In particular, a linearmodel was used for the anal-
ysis of the apoptosis data. For the evaluation of the in vivo anti-leukemic
activity of CD19L–sTRAIL, the probability of survival was determined
and the event-free interval curves were generated using the Kaplan–
Meier product limitmethod. Log-rank testswere performed to compare
differences in median survival estimates between all groups and
pairwise comparison of pooled controls vs. test mice treated with
CD19L–sTRAIL, TBI, or CD19L–sTRAIL + TBI. For the analysis of the
in vitro potency of CD19L–sTRAIL against leukemic stem cells in xeno-
graft specimens, two-tailed T-tests with correction for unequal variance
(Microsoft Excel) were performed comparing various parameters of
leukemic burden of the NS mice that were inoculated with the treated
vs. untreated xenograft cells, including the mean spleen size and cellu-
larity for the various treatments.
2.12. Study Approval
The animal research in mice was conducted according to Institu-
tional Animal Care and Use Committee (IACUC) Protocols 280-12
and 293-10 that were approved by the IACUC of CHLA. All animal
care procedures conformed to the Guide for the Care and Use of Lab-
oratory Animals (National Research Council, National Academy
Press, Washington DC 1996, USA). Leukemia cells isolated from
deidentiﬁed patient specimens were used in the described experi-
ments. The secondary use of leukemia cells for subsequent laborato-
ry studies did not meet the deﬁnition of human subject research per
45 CFR 46.102 (d and f) since it did not include identiﬁable private
information, and the corresponding research protocol CCI-10-
00141 was approved by the CHLA IRB (CCI) (Human Subject Assur-
ance Number: FWA0001914).
3. Results
3.1. CD19L–sTRAIL Plus Low Dose Radiation Induces Apoptosis in
Radiation-resistant Primary Human BPL Cells and BPL Xenograft Clones
We used a quantitative ﬂow cytometric apoptosis assay to examine
the ability of CD19L–sTRAIL (2.1 pM) plus low dose radiation with 50–
200 cGy (i.e., 0.5–2 Gy) γ-rays to cause apoptotic death in freshly
obtained primary leukemic cells from patients with BPL (N = 17) as
well as very aggressive in vivo clonogenic human leukemic B-cell pre-
cursors isolated from the spleens of xenograftedNSmice that developed
overt leukemia after inoculation with primary leukemic blast cells from
patients with BPL (N=10) in side by side comparisonwith 50–200 cGy
γ-rays administered in a single dose. Although we observed a dose-
dependent apoptosis in irradiated samples of BPL xenograft cells (P =
0.0149 for 5.35± 1.59% apoptosis at 50 cGy vs. 12.14± 3.46% apoptosis
at 200 cGy) (Fig. 1A) as well as primary BPL cells (combined dataset: P-
value = 0.0028 for 10.4 ± 4.9% apoptosis at 50 cGy vs. 32.9 ± 6.6%apoptosis at 200 cGy), even 200 cGy γ-rays killed only 45 ± 9% of pri-
mary BPL cells (N = 17) and 12 ± 3% of BPL xenograft cells (N = 10).
The average percentage of apoptotic leukemia cells after 200 cGy γ-
rays was 33 ± 7% for all 27 samples combined (Fig. 1B). These results
are in accord with previous reports and conﬁrm that BPL cells are
radiation-resistant with SF2 (surviving fraction at 2 Gy) values N 0.5
(Uckun et al., 1993a,b, 2013). CD19L–sTRAIL (2.1 pM) consistently
caused apoptosis in these radiation-resistant human BPL cell popula-
tions with 89 ± 6% (N = 17) apoptosis for primary BPL cells, 97 ± 2%
(N = 10) for BPL xenograft cells, and 92 ± 4% (N = 27) for the entire
sample size (P b 0.0001 vs. 200 cGy γ-rays). The in vitro potency of
the CD19L–sTRAIL fusion protein and the limited sensitivity of the apo-
ptosis assay platform prevented an accurate assessment of the potential
of the combination therapy vs. CD19L–sTRAIL alone using these in vitro
tests (Fig. 1B).
3.2. CD19L–sTRAIL Plus Low Dose Radiation Kills Leukemia-initiating Cells
(LICs) in BPL Xenograft Samples
We compared the effects of CD19L–sTRAIL (2.1 pM × 24 h) (N =
14), ionizing radiation (2 Gy) (N = 11), and CD19L–sTRAIL + ionizing
radiation (N= 4) on the ability of LICs representing the putative leuke-
mic stem cell subpopulation of radiation-resistant BPL xenograft clones
to initiate leukemia in immunodeﬁcient NS mice. Controls included 12
mice inoculated with untreated xenograft cells. Whereas all 12 control
mice receiving untreated BPL xenograft cells developed leukemia, only
5 of 11 mice receiving irradiated BPL xenograft cells and only 2 of the
14 mice receiving CD19L–sTRAIL treated BPL xenograft cells developed
leukemia (P = 0.0008 for radiation vs. CON; P b 0.0001 for CD19L–
sTRAIL vs. CON). Although none of the 4 mice injected with xenograft
cells exposed to a combination of CD19L–sTRAIL + radiation developed
leukemia, the in vitro potency of the fusion protein prevented an accu-
rate assessment of the potential of the combination therapy. Spleen
counts were signiﬁcantly reduced with CD19L–sTRAIL+ 2 Gy radiation
compared to control (Independent T-test, Df = 14, T value = 4.415,
P = 0.0006; Linear Contrast, P = 0.0004). Strong trends were observed
for the reduction in spleen count comparing radiation alone (Indepen-
dent T-test, Df = 9.22, T value = 1.917, P = 0.087; Linear Contrast,
P = 0.041) or CD19L–sTRAIL alone (Independent T-test, Df = 16, T
value = 1.984, P = 0.065; Linear Contrast, P = 0.17) vs. combination
of radiation + CD19L–sTRAIL. The combination group had the lowest
(albeit not signiﬁcantly lower than the radiation or CD19L–sTRAIL
groups) average leukemia burden (6.8 ± 3.4 × 106 cells per spleen).
The measured values for other groups were 347.8 ± 106.1 × 106 cells
per spleen for the CON group (P = 0.0004 vs. the combination group),
213.7 ± 128.8 × 106 cells per spleen for the radiation group (P =
0.041 vs. the combination group), and 26.3±12.9 × 106 cells per spleen
for the CD19L–sTRAIL group (P = 0.0006 vs. CON, P = 0.065 vs. the
combination group) (Fig. 1C).
3.3. CD19L–sTRAIL Plus Low Dose TBI is Safe and Prevents the Development
of Fatal Leukemia in a NS Mouse Model of Relapsed BPL
The limited sensitivity of the in vitro apoptosis assays and the re-
markable single agent anti-leukemic potency of CD19L–sTRAIL did not
allow an accurate assessment of potential additive or synergistic effects
between CD19L–sTRAIL and radiation in vitro. Therefore, we next set
out to determine if CD19L–sTRAIL can augment the anti-leukemic
potency of TBI against BPL cells in vivo. We ﬁrst examined the in vivo
toxicity and short-term anti-leukemic activity of CD19L–sTRAIL plus
low dose TBI (2 Gy) in a feasibility study employing 2 separate NS
xenograft models of relapsed human BPL. In both models, xenografted
human BPL has a very aggressive course and progresses rapidly.
CD19L–sTRAIL was administered i.v. for 2 consecutive days (days 1
and 2), at a non-toxic total dose level of 17 fmol per kg per day after
the administration of an invariably fatal dose (2 × 106 cells per
Fig. 2. In vivo anti-leukemic activity and toxicity of CD19L–sTRAIL alone or in combination
with lowdose TBI inNSmousemodels of relapsedBPL. NSmice (5 per group per xenograft
model × 2 models; 10 mice per treatment group cumulatively) were inoculated with
2 × 106 xenograft cells derived from 2 relapsed BPL patients. CD19L–sTRAIL was adminis-
tered intravenously for 2 days (days 1 and 2) at a non-toxic daily dose level of 17 fmol per
kg per day. One of the treatment groups received TBI (2 Gy, day 2) and one group received
CD19L–sTRAIL (17 fmol per kg per day × 2 days, days 1 and 2) + 2 Gy TBI on day 2. The
experiment was terminated by euthanasia of all mice in all treatment groups when
untreated control mice (CON) showed signs of morbidity. Depicted are the bar graphs
showing the mean values for the nucleated spleen cell count and absolute lymphocyte
count (ALC) as surrogate measures of the leukemia burden. Pairwise Independent
Student's T-tests (unequal variance correction) were performed to calculate P-values
comparing CD19L–sTRAIL andCD19L–sTRAIL+ lowdose TBI groupswith other treatment
groups.
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All untreated control mice (N = 10) as well as all low dose TBI-
treated mice (N = 10) – but none of the 10 CD19L–sTRAIL + low
dose TBI treated mice – developed severe morbidity due to overt leuke-
mia by day 19 (Fisher's exact, two-tailed, P b 0.0001). Likewise, none of
the mice treated with CD19L–sTRAIL alone developed morbidity due to
treatment toxicity or overt leukemia. CD19L–sTRAIL plus low dose TBIexhibited potent anti-leukemic activity, as measured by normal ALCs
values with the absence of circulating leukemia cells (Fig. 2A & B) as
well as normal nucleated spleen cell counts (Fig. 2C). The average
ALCs was 0.31 ± 0.08 × 103 per μL (WBC: 0.9 ± 0.2 × 103 per μL) for
non-leukemic control NS mice that were not inoculated with human
leukemia cells. By comparison, the average ALCs of untreated CON NS
mice that were inoculated with ALL xenograft cells was 5.3 ±
1.6 × 103 per μL (WBC: 9.1 ± 2.6 × 103 per μL) due to circulating leuke-
mia cells. Likewise, TBI-treated mice had high ALCs values (albeit lower
than those in untreated controls) due to circulating leukemia cells. In
contrast to the CON or low dose TBI alone groups of mice, test mice
treated with CD19L–sTRAIL + low dose TBI had ALCs values (0.56 ±
0.06 × 103 per μL, P = 0.0146) and WBC (1.3 ± 0.1 × 103 per μL, P =
0.0144) values that were within the normal range (Fig. 2A & B). Control
mice developed overt disseminated leukemiawithmassive splenomeg-
aly and an average nucleated spleen cell count of 178± 60 × 106 (Log10
count: 7.8±0.3) thatwas signiﬁcantly higher than thenucleated spleen
counts of non-leukemic control NS mice (4.6 ± 0.4 × 106, Log10 count:
6.6 ± 0.4, P b 0.0001) (Fig. 2C). In mice treated with CD19L–
sTRAIL + low dose TBI, the nucleated spleen cell count was only
3.3 ± 1.0 × 106 (Log10 count: 6.3 ± 0.9), which was signiﬁcantly
lower than the spleen cell counts of CON mice (P = 0.0002) or mice
treated with low dose TBI alone (57.1 ± 17.0, Log10 count: 7.4 ± 0.2,
P = 0.0006) (Fig. 2C). The ALCs (P = 0.9) as well as nucleated spleen
cell counts (P = 0.7) of mice treated with CD19L–sTRAIL alone were
similar to those of mice treated with CD19L–sTRAIL + low dose TBI
(Fig. 2).
There was no clinical or laboratory evidence of moderate-severe
acute toxicity associated with the CD19L–sTRAIL + low dose TBI treat-
ments (Fig. 3, Table S1). We performed detailed histopathological ex-
amination of multiple tissues from each of 20 NS mice inoculated with
ALL xenograft cells derived from a relapsed BPL patient (5 untreated, 5
TBI-treated, 5 CD19L–sTRAIL treated and 5 CD19L–sTRAIL+ TBI treated
mice). All of the untreated but none of the CD19L–sTRAIL + TBI treated
mice showedmicroscopic evidence of disseminated leukemia involving
their bone marrow and at least one of the other 4 target organ sites ex-
amined (viz., lymph node, thymus, brain, spinal cord) (2 Tailed Fisher's
exact, P b 0.0001). Disseminated leukemia was also found in 4 of 5 TBI-
treated mice, as documented by thymic inﬁltration. No toxic lesions
suggestive of signiﬁcant parenchymal organ damage were detected in
any of the 18 organs examined in CD19L–sTRAIL + TBI treated mice
(Table S1). Mild bile duct proliferation was found in one of the
CD19L–sTRAIL treated mice but not in any of the other mice (Fig. S3).
One of 5 mice treated with CD19L–sTRAIL + TBI had minimal hepato-
cellular degeneration and necrosis in the perivenular location (Fig. S3).
3.4. CD19L–sTRAIL Plus Low Dose TBI Improves the Event-free Survival
Outcome in a NS Mouse Model of Advanced Relapsed BPL
Intravenous inoculation of NS mice with 2 × 106 cells of the xeno-
graft UCN3 derived from a relapsed BPL patient causes rapidly progres-
sive fatal BPL with diffuse bonemarrow involvement becoming evident
within 7 days. Treatments were initiated on day 10 after the inoculation
of 2 × 106 xenograft cells unless mice developed signs of leukemia-
associated morbidity. The median EFS for this CD19L–sTRAIL + low
dose TBI group was 72 days, which was signiﬁcantly longer than the
EFS for the untreated control group CON (17 days, P b 0.0001), TBI
alone group (64 days, P = 0.0014), CD19L–sTRAIL alone group
(20 days, P = 0.0022), or standard VDL chemotherapy group treated
with a combination of Vincristine (0.05 mg per kg) + Dexamethasone
(2 mg per kg) + PEG-Asparaginase (850 IU per kg) (17 days, P =
0.0033) (Fig. 4). No mouse in the CD19L–sTRAIL plus TBI group experi-
enced a toxic death or signs of treatment related toxicity. At 64 days, the
EFS ratewas 0±0% ofmice in the CON or VDL groups, 18± 12% ofmice
in the TBI alone group and 6 ± 6% of mice in the CD19L–sTRAIL alone
group. In contrast, the EFS rate was 63 ± 18% (95% conﬁdence
Fig. 3. In vivo safety of CD19L–sTRAIL alone or in combination with low dose TBI in NS mouse models of relapsed BPL. NS mice (5/group/xenograft model × 2 models; 10 mice/treatment
group cumulatively) were inoculatedwith 2 × 106 xenograft cells derived from 2 relapsed BPL patients. CD19L–sTRAIL was administered intravenously for 2 days (days 1 and 2) at a non-
toxic daily dose level of 17 fmol per kg per day. One of the treatment groups received TBI (2 Gy, day 2) and one group received CD19L–sTRAIL (17 fmol per kg per day × 2 days, days 1
and 2) + 2 Gy TBI on day 2. The experiment was terminated by euthanasia of all mice in all treatment groups when untreated control mice (CON) showed signs of morbidity. Depicted
are the bar graphs showing themean values for each organ function parameter determined. Pairwise Independent Student's T-tests (unequal variance correction)were performed to cal-
culate P-values comparing CD19L–sTRAIL and CD19L–sTRAIL + low dose TBI groups with other treatment groups. CD19L–sT: CD19L–sTRAIL.
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TBI, which was superior to the EFS outcome in any other group (Log
rank test, CD19L–sTRAIL + TBI versus all other groups combined, P =
0.0001). These results provided the preclinical proof-of-concept that
CD19L–sTRAIL plus lowdose TBIwould be a safe and effective treatment
modality for the treatment of relapsed BPL. The combination treatment
was able to overcome the radiation resistance of the leukemia cells and
it was more effective than the VDL combination chemotherapy in this
model of advanced stage relapsed BPL. We hypothesize that the incor-
poration of CD19L–sTRAIL into the pre-transplant TBI regimens of pa-
tients with relapsed BPL will help improve their survival outcome
after hematopoietic stem cell HSCT.
3.5. CD19L–sTRAIL Plus Low Dose TBI Improves the Survival Outcome in a
CD22ΔE12xBCR-ABL Double Transgenic Model of Advanced Murine BPL
There is a 57.5% identity of the extracellular domain of the mouse
and human CD19 proteins. CD19L–sTRAIL showed signiﬁcant binding
to the surface of highly radiation-resistant CD19+ murine BPL cells
from CD22ΔE12xBCR-ABL double-Tg mice (Fig. S2C) and induced 42–
66% apoptosis within 24 h (Fig. S2D). CD19L–sTRAIL + low dose
(2 Gy) radiation in vitro was markedly more effective than CD19L–
sTRAIL alone or low dose radiation alone and caused 88–94% apoptosis
(Fig. S2D). Therefore, the CD22ΔE12xBCR-ABL double-Tg mouse model
provides a unique opportunity to study the clinical potential of CD19L–
sTRAIL plus low dose TBI as a new treatment modality for radiation-resistant BPL in a host with a healthy immune system devoid of the in-
herent shortcomings of the NS mouse xenograft models. Furthermore,
murine BPL cells are DR4− and show weaker binding to CD19L–sTRAIL
than human BPL cells. Therefore, this murine BPL model also provides
an opportunity to search for combination regimens that would over-
come CD19L–sTRAIL resistance in clinical settings due to reduced ex-
pression levels of DR4 and CD19. We randomly assigned mice to one
of 4 treatment protocols when they developed symptomatic leukemia
or measurable tumor masses. As shown in Fig. 5, the combination of
CD19L–sTRAIL (17 fmol per kg per day × 3 days or 17 fmol per kg per
day single dose) with 4 Gy TBI yielded PFS and TFS outcomes signiﬁ-
cantly superior to those of untreated controlmice (CON) ormice treated
with TBI alone or CD19L–sTRAIL alone.
The comparison of the cumulative tumor progression curves for the
CON group vs. CD19L–sTRAIL+ TBI group showed a rapid regression of
tumor size and a markedly favorable alteration of the disease course
over a period of 14 days (RepeatedMeasures ANCOVA, treatment effect,
F1,10.8 = 153.7, P b 0.0001). We observed a greater than 1.5-fold in-
crease of tumor size in CON mice within 4 days, whereas the tumors
of the mice in the CD19L–sTRAIL + TBI group rapidly regressed within
4 days and remained undetectable for 14 days after each course of treat-
ment (Fig. 5B). The mean ± SE values for PFS were 24.0 ± 4.0 days for
CD19L–sTRAIL + TBI, but only 0 ± 0 days for CON (Non-parametric
Wilcoxon test, P b 0.0001), 3.4 ± 0.9 days for CD19L–sTRAIL alone
(P = 0.0003), and 9.0 ± 4.6 days for TBI (P = 0.020) (Fig. 5C). Five of
5 mice treated with a single dose of CD19L–sTRAIL + single dose TBI
Fig. 4. CD19L–sTRAIL plus low dose TBI against chemotherapy-resistant BPL. Depicted are the EFS curves of NSmice that were inoculated i.v. with xenograft cells (2 × 106 cells per mouse)
derived fromprimary leukemia cells of a relapsed BPL patient. Sixteen testmicewith symptomatic xenografted BPLwere treatedwith CD19L–sTRAIL+TBI (Schedule 1: CD19L–sTRAIL on
days 10,11 and 12; TBI on day 11, N = 6; Schedule 2: CD19L–sTRAIL on day 6; TBI on day 7, N = 5; Schedule 3: CD19L–sTRAIL on days 6 and 7; TBI on day 7, N = 5). Besides untreated
mice (N = 11), additional controls included mice treated with CD19L–sTRAIL alone (N = 23), TBI alone (N = 11), or 3-drug combination chemotherapy VDL
(Vincristine + Dexamethasone + PEG-Asparaginase) (N = 7). The probability of survival was determined and the event-free interval curves were generated using the Kaplan–Meier
product limit method. Log-rank tests were performed to compare differences in median survival estimates between all groups and pairwise comparisons. P-values for pairwise compar-
isons for the CD19L–sTRAIL + TBI group versus each of the other 4 groups exhibited signiﬁcant increases in survival times for all the comparisons. CD19L–sT: CD19L–sTRAIL.
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rapidly achieved a remission (time to remission: 3.3 ± 0.5 days). By
comparison, only 3 of 6 mice treated with TBI alone (Fisher's exact
test, P = 0.03) and none of the 8 mice treated with CD19L–sTRAIL
alone achieved remission (P b 0.0001). The duration of remission as
measured by the TFS times were 21.7 ± 3.9 days for CD19L–
sTRAIL + TBI, but only 7.2 ± 3.9 days for TBI alone (Non-parametric
Wilcoxon test, P = 0.0172) and 0.0 ± 0.0 days for CON (P b 0.0001)
or CD19L–sTRAIL alone (P= 0.0002) (Fig. 5C). Twomice on the combi-
nation regimen relapsed and achieved a second remission after a single
dose of CD19L–sTRAIL + TBI (Mouse #1: Remission 1: 19 days, Remis-
sion 2: 13 days;Mouse #2: Remission 1: 18 days, Remission 2: 12 days).
Due to the consistent remission induction and prolonged remissions, the
overall survival (OS) time was much longer for the CD19L–sTRAIL + TBI
group than for the other groups (Fig. 5D). The survival outcome as mea-
sured by the number of days the mice remained alive after the onset of
symptomatic leukemia/1st day of treatment showed a markedly im-
proved outcome after CD19L–sTRAIL+TBI vs. TBI alone or CD19L–sTRAIL
alone. The median OS times were 29 days for CD19L–sTRAIL + TBI but
only 4 days for CON (Log-rank test, P b 0.0001), 7.5 days for CD19L–
sTRAIL alone (P b 0.0001), and 13.5 days for TBI alone (P = 0.0021).
We also treated 3 leukemic mice with Imatinib daily for 3 consecutive
days (daily i.v. dose: 120 mg per kg in PBS = the mouse equivalent
dose for the 340 mg per m2 per day dose level used in recent studies on
Ph+ ALL patients) as an additional control treatment group: There were
no remissions and no meaningful prolongation of PFS (mean ± SE =
3.0 ± 0.0 days) or OS (median survival: 8 days) in the Imatinib group
(Fig. 5). These results extended the data obtained in the NS mouse xeno-
graft model and provided further preclinical proof-of-concept that
CD19L–sTRAIL plus low dose TBI would be a safe and effective treatment
modality in the treatment of radiation-resistant BPL.
4. Discussion
TBI-based conditioning regimens have not prevented leukemic re-
lapses post-HSCT (Uckun et al., 1993a; Pulsipher et al., 2009; Balduzzi
et al., 2014; Bar et al., 2014; Bachanova et al., 2012). Therefore, the iden-
tiﬁcation of new drugs that can help overcome the radiation resistanceof BPL cells would be an important step forward in efforts aimed at im-
proving the post-HSCT outcomes. We hypothesize that the incorpora-
tion of CD19L–sTRAIL into the pre-transplant TBI regimens of patients
with recurrent or high-risk BPLwill help overcome the radiochemother-
apy resistance of their leukemia cells and thereby improve their treat-
ment response and survival outcome after HSCT. In the present study,
the combination of CD19L–sTRAIL with 2 Gy TBI in NS mice or 4 Gy
TBI in CD22ΔE12xBCR-ABL double-Tg mice was very well tolerated
without any treatment related morbidity or toxic deaths. In xenografted
NSmice treatedwith CD19L–sTRAIL+ 2Gy TBI, therewere no treatment
related deaths, andblood tests did not reveal changes suggestive of signif-
icant hematologic, renal, pancreatic, or hepatic toxicity. Furthermore, his-
topathological evaluations did not show treatment-related toxic lesions
suggestive of signiﬁcant parenchymal organ damage in any of the
organs examined. Therefore, it should be feasible to use this CD19L–
sTRAIL + 2 Gy TBI module in place of 2 Gy in fractionated TBI regimens.
Monoclonal antibodies and their fragments can cause potentially
life-threatening immunotoxicity, including cytokine storms, anaphylax-
is and anaphylactoid reactions, as well as autoimmunity. CD19L–sTRAIL
is not a monoclonal antibody-based therapeutic agent but it is plausible
that it could also cause similar side effects in clinical settings due to its
immunogenicity as a fusion protein. Therefore, it will be important to
carefully examine its potential immunotoxicological effects in pharma-
cologically relevant animal species prior to a ﬁrst-in-human clinical
trial. Furthermore, biotherapeutic agents can sometimes trigger activa-
tion of the innate immune system and a toll-like-receptor response or
cause a potentially fatal inﬂammatory response with a “cytokine
storm”. The use of CD19L–sTRAIL higher dose levels and prolonged
schedules may cause unexpected side effects alone and/or in combina-
tion with low dose TBI in clinical settings.
The demonstrated ability of CD19L–sTRAIL tomarkedly augment the
anti-leukemic potency of low dose TBI, induce remissions and improve
the EFS outcome in two separate models of radiation-resistant BPL
without serious added toxicity provides the preclinical proof of concept
for CD19L–sTRAIL plus reduced intensity TBI with total doses as low as
6 Gy as a new conditioning regimen that has the potential to signiﬁcant-
ly improve the EFS outcome and long-term health status of high-risk re-
mission BPL patients undergoing HSCT.
Fig. 5. Anti-leukemic activity of CD19L–sTRAIL plus low dose TBI against murine B-precursor leukemia in CD22ΔE12xBCR-ABL double-Tg mice. The CD19L–sTRAIL + TBI (N = 11) test
group (Group d) was compared to untreated control mice (N = 12) (Group a). Additional controls included mice treated with CD19L–sTRAIL alone (N = 8) (Group c), TBI alone
(N=6) (Group b), or Imatinib alone (N=3) (Group e). [A] Depicted are the day 1 vs. day 7 images of representative CD22ΔE12xBCR-ABL double-Tgmice assigned to different treatment
protocols. [B] Tumor sizes of untreated control mice vs. mice treated with CD19L–sTRAIL (17 fmol per kg per day × 3 days or 17 fmol per kg per day single dose) + 4 Gy TBI were deter-
mined using the longest diameter measurement of each tumor in the mice and normalized to the pre-treatment tumor size on day 1. Depicted are the values for normalized tumor size
during theﬁrst 14 days after the initiation of treatment. The repeatedmeasures analysis of co-variancemodel explained signiﬁcant proportion of the variance in the growth proﬁles with a
highly signiﬁcant difference between CON and CD19L–sTRAIL+ TBI groups (72% of the variance explained, F1,10.8= 153.7, P b 0.0001). [C] Tumor-free survival (C) (in days) and progres-
sion-free survival (D) (in days) distributions are depicted using Quantile dot plots (box represents 25th,median and 75th percentiles, and thewhiskers represent theminimum, 10th, 90th
andmaximumvalues). Pair-wise differences inmedian survival timeswere calculated using Non-parametricWilcoxon tests. [D] The survival outcome asmeasured by the number of days
themice remained alive after the onset of symptomatic leukemia is depicted by interval curves generated using the Kaplan–Meier product limit method and the P-values were calculated
using Log-rank tests to take into account censored data in the CD19L–sTRAIL + TBI arm and the 3 animals censored at 18, 25 and 60 days were included in the curve.
315F.M. Uckun et al. / EBioMedicine 2 (2015) 306–316Themain focus of our studywas to design a potent reduced intensity
TBI-based pre-transplant conditioning regimen for BPL. However,
CD19L–sTRAIL + TBI may also serve as a major component of pre-
transplant conditioning strategies for other forms of poor prognostic
B-lineage lymphoid malignancies owing to the abundant expression of
CD19 on neoplastic cells from non-Hodgkin's lymphoma patients and
other forms of B-lineage leukemias as well (Uckun et al., 1988; D'Cruz
and Uckun, 2013).Author Contributions
All authors have made signiﬁcant and substantive contributions to
the study. All authors reviewed and revised the paper. F.M.U. was theNIH-funded Principal Investigator who designed, directed and super-
vised this study and wrote the initial draft of the manuscript. S.Q. per-
formed the statistical analyses and PK parameter determinations. R.R.
(DVM, PhD, Diplomate ACVP) performed the histopathological exami-
nation of the mouse tissues. D.E.M. puriﬁed CD19L–sTRAIL and Fc-
tagged CD19L proteins; she also performed the ﬂuorescent labeling of
CD19L–sTRAIL and sTRAIL. H.M. prepared the CD19L–sTRAIL plasmid
and coordinated its expression.Acknowledgments
F.M.U. was supported in part by DHHS grants P30CA014089, U01-
CA-151837, R01CA-154471 and R21-CA-164098 (F.M.U.) from the
316 F.M. Uckun et al. / EBioMedicine 2 (2015) 306–316National Cancer Institute; and the V-Foundation, Nautica Triathalon, as
well as Ronald McDonald House Charities of Southern California. The
content is solely the responsibility of the authors and does not necessar-
ily represent the ofﬁcial views of the National Cancer Institute or the
National Institutes of Health. There was no ﬁnancial or non-ﬁnancial
support from pharmaceutical companies, corporations or other entities.
No funder had an interest in or control over the study design, data col-
lection and analysis, or reporting. We thank Martha Arellano, Erin
Feinstone, Cherish Flowers, Anoush Shahidzadeh, Ingrid Cely, and
Erika Olson from the Uckun Lab at the Children's Center for Cancer
and Blood Diseases/CHLA for technical assistance. We further thank
Mrs. Parvin Izadi of the CHLA Bone Marrow Laboratory, Mrs. Tsen-Yin
Lin of the CHLA FACS Core, as well as Ernesto Barron and Anthony
Rodriguez of the USC Norris Comprehensive Cancer Center Cell and Tis-
sue Imaging Core for their assistance. We also thank Drs. Amanda
Termuhlen and Paul Gaynon for providing primary BPL specimens.
Appendix A. Supplementary Data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.02.008.
References
Asselin, B.L., Gaynon, P., Whitlock, J.A., 2013. Recent advances in acute lymphoblastic leu-
kemia in children and adolescents: an expert panel discussion. Curr. Opin. Oncol.
(Suppl. 3), S1–S13 http://dx.doi.org/10.1097/CCO.0000000000000017 (quiz S14-6).
Bachanova, V., Burke, M.J., Yohe, S., Cao, Q., Sandhu, K., Singleton, T.P., Brunstein, C.G.,
Wagner, J.E., Verneris, M.R.,Weisdorf, D.J., 2012. Unrelated cord blood transplantation
in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual dis-
ease on relapse and survival. Biol. Blood Marrow Transplant. 18, 963–968.
Balduzzi, A., Di Maio, L., Silvestri, D., Songia, S., Bonanomi, S., Rovelli, A., Conter, V., Biondi,
A., Cazzaniga, G., Valsecchi, M.G., 2014. Minimal residual disease before and after
transplantation for childhood acute lymphoblastic leukemia: is there any room for
intervention. Br. J. Haematol. 164, 396–408.
Bar, M., Wood, B.L., Radich, J.P., Doney, K.C., Woolfrey, A.E., Delaney, C., Appelbaum, F.R.,
Gooley, T.A., 2014. Impact of minimal residual disease, detected by ﬂow cytometry,
on outcome of myeloablative hematopoietic cell transplantation for acute lympho-
blastic leukemia. Leukemia Res.Treat. http://dx.doi.org/10.1155/2014/421723 (Arti-
cle ID: 421723).
Bernard, F., Auquier, P., Herrmann, I1., Contet, A., Poiree, M., Demeocq, F., Plantaz, D.,
Galambrun, C., Barlogis, V., Berbis, J., Garnier, F., Sirvent, N., Kanold, J., Chastagner,
P., Chambost, H., Michel, G., 2014. Health status of childhood leukemia survivors
who received hematopoietic cell transplantation after BU or TBI: an LEA study.
Bone Marrow Transplant. 49, 709–716. http://dx.doi.org/10.1038/bmt.2014.3 (Epub
2014 Feb 17).
Bremer, E., 2013. Targeting of the tumor necrosis receptor superfamily for cancer immu-
notherapy.. (Review Article), ISRN Oncology. http://dx.doi.org/10.1155/2013/371854
(Article ID: 371854).
D'Cruz, O.J., Uckun, F.M., 2013. Novel mAb-based therapies for leukemia. In: Uckun, F.M.
(Ed.), Monoclonal Antibodies in Oncology. Future Medicine. Future Medicine Ltd,
London, pp. 54–77 http://dx.doi.org/10.2217/ebo.13.218.
Dimberg, L.Y., Anderson, C.K., Camidge, R., Behbakht, K., Thorbum, A., Ford, H.L., 2013. On
the TRAIL to successful cancer therapy? Predicting and counteracting resistance
against TRAIL-based therapeutics. Oncogene 32 (11), 1341–1350. http://dx.doi.org/
10.1038/onc.2012.164.
Fox, N.L., Humphreys, R., Luster, T.A., Klein, J., Gallant, G., 2010. Tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for can-
cer therapy. Expert. Opin. Biol. Ther. 10 (1), 1–18. http://dx.doi.org/10.1038/sj.bjc.
6605987.
Gaynon, P.S., Harris, R.E., Altman, A.J., Bostrom, B.C., Brenneman, J.C., Hawks, R., Steele, D.,
Zipf, T., Stram, D.O., Villaluna, D., Trigg, M.E., 2006. Bone marrow transplantation
versus prolonged intensive chemotherapy for children with acute lymphoblastic
leukemia and an initial bone marrow relapse within 12 months of the completion
of primary therapy: Children's Oncology Group Study CCG-1941. J. Clin. Oncol. 24,
3150–3156.Gong, B., Almasan, A., 2000. Apo2 ligand/TNF-related apoptosis-inducing ligand and death
receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic
cells. Cancer Res. 60 (20), 5754-60.
Kalaycio, M., Bolwell, B., Rybicki, L., Absi, A., Andresen, S., Pohlman, B., Dean, R., Sobecks,
R., Copelan, E., 2011. BU- vs TBI-based conditioning for adult patients with ALL.
Bone Marrow Transplant. 46, 1413–1417.
Kruyt, F.A.E., 2008. TRAIL and cancer therapy (Mini-review). Cancer Lett. 263, 14–25.
Locatelli, F., Schrappe, M., Bernardo, M.E., Rutella, S., 2012. How I treat relapsed childhood
acute lymphoblastic leukemia. Blood 120, 2807–2816. http://dx.doi.org/10.1182/
blood-2012-02-265884.
Marks, D.I., Forman, S.J., Blume, K.G., et al., 2006. A comparison of cyclophosphamide and
total body irradiation with etoposide and total body irradiation as conditioning regi-
mens for patients undergoing sibling allografting for acute lymphoblastic leukemia in
ﬁrst or second complete remission. Biol. Blood Marrow Transplant. 12, 438–453.
Merino, D., Lalaoui, N., Morizot, A., Solary, E., Micheau, O., 2007. TRAIL in cancer therapy:
present and future challenges. Expert Opin. Ther. Targets 11, 1299–1314.
Mori, T., Aisa, Y., Kato, J., Yamane, A., Nakazato, T., Shigematsu, N., Okamoto, S., 2012. Safe-
ty and efﬁcacy of total body irradiation, cyclophosphamide, and cytarabine as a con-
ditioning regimen for allogeneic hematopoietic stem cell transplantation in patients
with acute lymphoblastic leukemia. Am. J. Hematol. 87, 349–353.
Pulsipher, M.A., Bader, P., Klingebiel, T., Cooper, L.J., 2009. Allogeneic transplantation for
pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation
minimal residual disease/chimerism monitoring and novel chemotherapeutic, mo-
lecular, and immune approaches aimed at preventing relapse. Biol. Blood Marrow
Transplant. 15, 62–71.
Tracey, J., Zhang, M.J., Thiel, E., Sobocinski, K.A., Eapen, M., 2013. Transplantation condi-
tioning regimens and outcomes after allogeneic hematopoietic cell transplantation
in children and adolescents with acute lymphoblastic leukemia. Biol. Blood Marrow
Transplant. 19, 255–259.
Uckun, F.M., Jaszcz, W., Ambrus, J.L., Fauci, A.S., Gajl-Peczalska, K., Song, C.W., Wick, M.R.,
Myers, D.E., Waddick, K., Ledbetter, J.A., 1988. Detailed studies on expression and
function of CD19 surface determinant by using B43 monoclonal antibody and the
clinical potential of anti-CD19 immunotoxins. Blood 71, 13–29.
Uckun, F.M., Jaszcz, W., Chandan-Langlie, M., Waddick, K.G., Gajl-Peczalska, K., Song, C.W.,
1993a. Intrinsic radiation resistance of primary clonogenic blasts from children with
newly diagnosed B-cell precursor acute lymphoblastic leukemia. J. Clin. Invest. 91,
1044–1051.
Uckun, F.M., Kersey, J.H., Haake, R., Weisdorf, D., Nesbit, M.E., Ramsay, N.K., 1993b.
Pretransplantation burden of leukemic progenitor cells as a predictor of relapse
after bone marrow transplantation for acute lymphoblastic leukemia. N. Engl.
J. Med. 329 (18), 1296–1301.
Uckun, F.M., Qazi, S., Ma, H., Tuel-Ahlgren, L., Ozer, Z., 2010a. STAT3 is a substrate of SYK
tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress.
Proc. Natl. Acad. Sci. U. S. A. 107 (7), 2902–2907.
Uckun, F.M., Goodman, P., Ma, H., Dibirdik, I., Qazi, S., 2010b. CD22 exon 12 deletion as a
novel pathogenic mechanism of human B-precursor leukemia. Proc. Natl. Acad. Sci. U.
S. A. 107, 16852–16857.
Uckun, F.M., Dibirdik, I., Qazi, S., 2010c. Augmentation of the anti-leukemic potency of
total body irradiation (TBI) by a novel P-site inhibitor of spleen tyrosine kinase
(SYK). Radiat. Res. 174, 526–531.
Uckun, F.M., Sun, L., Qazi, S., Ma, H., Ozer, Z., 2011a. Recombinant human CD19-ligand
protein as a potent anti-leukemic agent. Br. J. Haematol. 153, 15–23.
Uckun, F.M., Qazi, S., Ozer, Z., Garner, A.L., Pitt, J., Ma, H., Janda, K.D., 2011b. Inducing ap-
optosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by
targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response
signalling network. Br. J. Haematol. 153, 741–752.
Uckun, F.M., Ma, H., Zhang, J., Ozer, Z., Dovat, S., Mao, C., Ishkhanian, R., Goodman, P., Qazi,
S., 2012. Serine phosphorylation by SYK is critical for nuclear localization and tran-
scription factor function of Ikaros. Proc. Natl. Acad. Sci. U. S. A. 109, 18072–18077.
Uckun, F.M., Qazi, S., Cely, I., Sahin, K., Shahidzadeh, A., Ozercan, I., Yin, Q., Gaynon, P.,
Termuhlen, A., Cheng, J., Yiv, S., 2013. Nanoscale liposomal formulation of a SYK P-
site inhibitor against B-precursor leukemia. Blood 121, 4348–4354.
Uckun, F.M., Qazi, S., Ma, H., Yin, L., Cheng, J., 2014. A rationally designed CD22ΔE12-
siRNA nanoparticle for RNAi therapy in B-lineage lymphoid malignancies. EBioMed.
1, 141–155.
Uckun, F.M., Myers, D.E., Qazi, S., Ozer, Z., Rose, R., D'Cruz, O., Ma, H., 2015a. Recombinant
human CD19L–sTRAIL effectively targets B-cell precursor acute lymphoblastic leuke-
mia. J. Clin. Invest. http://dx.doi.org/10.1172/JCI76610.
Uckun, F.M., Ma, H., Cheng, J., Myers, D.E., Qazi, S., 2015b. CD22ΔE12 as a molecular target
for RNAi therapy. Br. J. Haematol. http://dx.doi.org/10.1111/bjh.13306.
Wissink, E.H., Verbrugge, I., Vink, S.R., Schader, M.B., Schaefer, U., Walczak, H., Borst, J.,
Verheij, M., 2006. TRAIL enhances efﬁcacy of radiotherapy in a p53 mutant, Bcl-2
overexpressing lymphoid malignancy. Radiother. Oncol. 80, 214–222.
